key: cord-0293001-25mae0g7
authors: Eddie, Alex M.; Chen, Kevin; Schenkel, Laurie B.; Swinger, Kerren K.; Molina, Jennifer R.; Kunii, Kaiko; Raybuck, Ariel L.; Keilhack, Heike; Niepel, Mario; Peebles, R. Stokes; Boothby, Mark R.; Cho, Sung Hoon
title: Selective pharmaceutical inhibition of PARP14 mitigates allergen-induced IgE and mucus overproduction in a mouse model of pulmonary allergic response
date: 2021-06-07
journal: bioRxiv
DOI: 10.1101/2021.06.05.447208
sha: 5953d50c3f0424a68b333c4faaaa104d5212f854
doc_id: 293001
cord_uid: 25mae0g7

The type 2 cytokines IL-4 and IL-13, which share use of an IL-4 receptor alpha chain and its nuclear induction of the transcription factor STAT6, are crucial in elicitation and maintenance of allergic conditions that include asthma. Prior work has shown a physical and functional association of STAT6 with PARP14, an ADP-ribosyl monotransferase. Moreover, elimination of all PARP14 expression by gene targeting led to altered recall antibody responses and attenuation of ovalbumin-specific allergic lung inflammation with no apparent health issues for mice lacking this protein. However, an unanswered question is whether or not inhibition of the catalytic function has any biological consequence since PARP14 has multiple functional domains apart from the portion that catalyzes ADP-ribosylation. As reported separately, iterative structural analyses and medicinal chemistry fostered the generation of a compound, RBN2759, that is highly selective in its inhibition of PARP14 with negligible impact on other members of the PARP gene family. We show here that administration of this compound to mice previously sensitized to the allergen Alternaria alternata achieved biochemically active levels and altered physiological responses to the antigen. These results show for the first time that in vivo administration of a specific inhibitor of the ADP-ribosyltransferase activity encoded by PARP14 is sufficient to alter biological responses. Specifically, the orally absorbable pharmaceutical compound decreased allergen-induced mucus, blunted the induced increases in circulating IgE, and prevented suppression of IgG2a. We conclude that the catalytic activity can contribute to pathogenesis in allergic processes and propose that other biological endpoints that depend on ADP-ribosylation by PARP14 can be targeted using selective inhibition.

Asthma, including allergen-induced forms of reversible obstructive airways disease, is a 44 highly prevalent condition (1-4). For example, approximately 25 million people in the US (5.5 45 million children and 19.2 million adults) exhibited evidence of this disease in a self-report survey 46

(1, 4). The standard of care in asthma -which includes inhaled corticosteroids that act on airway 47 inflammation through glucocorticoid nuclear receptors -commonly does not suffice to prevent 48 severe asthma attacks upon re-exposure to environmental allergens (5-7). Although the rates of 49 complete resistance to corticosteroids are low, even partial resistance can undermine long-term 50 health for asthmatic patients, making identification of additional treatments desirable. In 51 addition, strict adherence to regimens of inhaled corticosteroids has remained problematic: a 52 meta-analysis of research from 1985 to 2012 showed no significant improvements in overall 53 clinical success (5-9). Thus, despite a number of therapeutic advances and ongoing introduction 54 of new agents to complement inhaled glucocorticoids, a large burden of morbidity remains in 55 which manifestations of the disease are inadequately controlled, with over 3500 deaths caused by 56 asthma were reported in 2017 (4). 57

Much remains to be determined about the origins of allergic asthma and pathophysiology 58 of established disease. Although each state can exist independent of the other, there is substantial 59 overlap of asthma with prior atopy (10-13). Atopic or T2-endotype asthma patients typically 60 exhibit an increase in circulating IgE, which points to a contribution of the T helper subset 2 61 (Th2) of CD4 + T cells that secrete type 2 cytokines such as IL-4, IL-5, and IL-13 inasmuch as 62 IL-4 receptor stimulation is crucial for generation of . Within human asthma and 63 animal models of the disease pathogenesis, eosinophilic (Th2-like) and/or neutrophilic (Th17-64 like along with Th2) patterns of allergic lung inflammation (ALI) have been identified in patients 65 and mouse models (17) (18) (19) (20) . Of these, the eosinophilic-pattern disease has seen therapeutic 66 advances with parenteral administration of biologic drugs (e.g., anti-IL-5) whereas the 67 neutrophilic pattern is more associated with severe or glucocorticoid-resistant disease (21, 22) 68 and has seen less progress. Among unmet needs, progress on orally absorbable agents that could 69 mitigate allergic disease or asthma remains important. 70

During allergic responses, IL-4 and IL-13 production increase due to expansion of the 71 population of allergen-specific Th2 lymphocytes as well as an expansion of group 2 innate 72 lymphoid cells (ILC2). These pleiotropic cytokines act via IL-4Rα receptor complexes on cell 73

Histology, bronchoalveolar lavage fluid, and cytometry Serial sections (5 µm thickness, 158 positioning two sections per slide) of formalin-fixed, paraffin-embedded lung tissue were 159 deparaffinized with xylene, and then stained using Periodic Acid Schiff (9162B, Newcomer 160

Supply, Middleton WI). To score airway mucus semi-quantitatively, three fields were selected 161 for each sample in a manner masked as to sample identity. Images of all fields were then scored 162 independently by three individuals masked as to sample identity. A scale quantified as 0-3 (0, no 163 excess mucus; 1, marginal and occasional hyperplasia and mucus; 2, substantial and moderate 164 mucus cell hyperplasia and some airway mucus; 3, severe hypersecretion and airway plugging) 165 was used, and average scores for a given sample were generated from the three individual scores, 166 which most often were perfectly concordant and at most differed among each other by 1. The 167 average score for each subject was then used to calculate a mucus hypersecretion index. 168 Differential counts of bronchoalveolar lavage fluid samples, performed by a reader masked as to 169 sample identity, were analyzed after cytospin deposition on microscope slides and Richard-Allen 170

Three-Step staining [#3300, ]. 171 172 Measurements of cytokines and Ab Secreted IL-4 was measured using a matching antibody pair 173 (capture, Tonbo 70-7041-U500; detection, eBio # 13-7042-85) with color generated using 174 streptavidin-HRP (R&D Systems, Dx998) followed by Ultra-TMB reagent (Pierce; Thermo 175 #34028). Both the purified and biotinylated Abs were used at a concentration of 0.5 µg/well. 176 Supernatants were collected from 1.0 x 10 6 lung cells/mL media restimulated overnight with 177 plate-bound anti-CD3 (adsorbed to wells at 1.0 µg/ml in PBS) and soluble anti-CD28 (1.0 µg/ml) 178 (Tonbo Biosciences), as previously described (36, 59) . Dilution points for the ELISAs were 179 selected based on the linear range of standard curves with purified recombinant cytokine. 180

Cytokine levels in restimulated lung suspension also were measured by Th1/Th2/Th17 181 Cytometric Bead Array (BD 560485). Relative concentrations of circulating antibodies were 182 determined using plasma collected at the time of harvest. High affinity binding plates were 183 coated with purified Ab (0.5 µg/well) directed against Ig H+L (Southern Biotech) for IgG classes 184 or IgE (BD Pharmingen, #553413) or with Alternaria extract (0.1 µg/well). Quality control 185 testing indicated that only anti-Alternaria IgG1 yielded reliably specific signal. 186 187

Total RNA was extracted from frozen lung tissue using TRIZOL 188 (Invitrogen) and a Micro-BeadBeater 96 (Biospec). RNA concentration and purity were 189 measured using a NanoDrop. cDNA were synthesized from RNA (4 µg) using AMV Reverse 190 Transcriptase (Promega) , as described (36) Biotechnology, Santa Cruz, CA), were rinsed, and eluted proteins were analyzed by 204

immunoblotting. Filters were blocked with 5% milk in 0.05% Tween20 and incubated (2 hr at 20 205 C) with primary antibodies directed against the FLAG epitope tag, mouse actin, mouse PARP14, 206 and PAR/MAR (Cell Signaling Technologies #83732S) and rinsed. After incubation with 207 secondary antibodies (IRD800 or IRD680) and rinsing, indirect immune fluorescent bands were 208 visualized and quantitated using an Odyssey imaging system Lincoln NE) as described 209 (59) . 210 211 Cell cultures B cells were purified (90-95%) by negative selection with single-cell splenocyte 212 suspensions by using biotinylated anti-Thy1.2 mAb followed by streptavidin-conjugated 213 microbeads (BD Pharmingen). In brief, 0.75 x10 6 cells/mL were cultured in 3 mL of RPMI1640 214 medium (Gibco Cat. #23400-021) in a 6-well cell culture plate (Peak Serum Inc. Cat. #TR5000), 215 supplemented with recombinant mouse BAFF (10 ng/mL). B cells were activated and plasma 216 cell differentiation stimulated using anti-CD40 (BD Cat. #553788) (1 µg/mL) or LPS (Sigma 217 L2630) (1 µg/mL), supplemented with IL-4 (Peprotech Cat. #214-14) (10 ng/mL) and IL-5 218 (Peprotech Cat. #215-15) (10 ng/mL) as indicated. RBN2579, dissolved in 100% DMSO for 219 stock solutions (1 mM; 368 µg/mL). Cultures were treated with either DMSO or PARP14i (1 μM 220 or 0.33 µM RBN2759), added once daily. Cultures were harvested and counted on Day 5; 221 supernatants were collected for ELISA to quantify relative levels of antibody (IgG1, IgG2a, and 222 IgE). 223 224 Statistical Analysis Graphs and statistics were generated using PRISM software (GraphPad, 225 San Diego, CA). Averages were generated from results in five independent experiments (three 226 with male mice and two with females) with no exclusions of subjects; drop-out was only for 227 spontaneous mortality in the course of the experiment, the rate for which was not affected by 228 treatment with active compound as compared to vehicle. Two-way ANOVAs were performed on 229 the datasets across full dilution curves, followed at specific points on the curves by either a 230 Student's T-test or Welch's unpaired T-test, selected according to the variance between the two 231 populations for which the null hypothesis was tested. concurrently. Accordingly, we first validated the inhibitory capacity of RBN2759 by transfecting 250 cells with PARP14 expression vector (36) or a control, culturing in inhibitor or vehicle, and 251 immunoblotting extracted proteins with antibody recognizing mono-as well as poly-ADP-ribose 252 adducts on proteins (MAR and PAR, respectively) (Fig. 1C ). This analysis showed that inhibitor 253 treatment substantially reduced the auto-modification of over-expressed PARP14. In light of the 254 observed inhibition, we tested if the treatment of mice with orally delivered RBN2759 decreased 255 the intensity of anti-MAR/PAR bands in splenocytes of subject mice. This analysis revealed 256 multiple bands reproducibly decreased in samples from inhibitor-treated subjects compared to 257 controls (Fig. 1D ). PARP14 expression is increased by pro-inflammatory signals such as TNF-α 258 (41). This suggested a biological impact of inhibiting ADP-ribosylation in Alternaria-exposed 259 lung tissue should cause reduced PARP14, which was observed (Fig. 1E ). We conclude that this and in a few cases no hyper-secretion was detected, the median effect did not reduce scores to 277 the level of non-sensitized controls. Similarly, when Muc5a mRNA levels that encode a protein 278 component of mucus were measured by qPCR with cDNA prepared from the RNA of one lung 279 lobe, these were lower in Alternaria-challenged mice treated with active compound when 280 compared to vehicle-treated controls. We conclude that the mucus over-production after 281 challenge with Alternaria antigens was reduced by selective in vivo inhibition of the capacity of 282 PARP14 to execute ADP-ribosylation. 283 284 Effect of RBN2759 on Alternaria-induced immune cell profiles uncoupled from mucus 285

In analyses of broncho-alveolar lavage (BAL) of patients with active disease, atopic 287 asthmatics commonly have increased eosinophils in their airways (62, 63); a similar effect is 288 typical in mouse models of allergic lung inflammation. Accordingly, we analyzed differential 289 counts of the cells recovered by unilateral BAL after clamping one mainstem bronchus. As 290 expected, the fractions of recovered cells that were eosinophils were substantially greater in 291

Alternaria-sensitized and rechallenged mice (Fig. 3 ). The type 2 inflammatory cytokines IL-4 292 and IL-13 are major drivers of mucus over-production, and eosinophil recruitment and survival 293 are promoted by IL-4 and the type 2 cytokine 30, 64) . Surprisingly, 294 however, no effect of the PARP14 inhibitor was observed for the BAL samples from the same 295 mice as clearly had reduced mucus (Fig. 3) . Some evidence suggests that inhibition of the drivers 296 of type 2 inflammation may increase Th17 responses or the neutrophil recruitment that is 297 enhanced by IL-17 (65). However, RBN2759 treatment at this dose did not change frequencies 298 of neutrophils in the BAL fluids recovered from Alternaria-challenged mice. Such mouse 299 models often also have increased immune cell infiltration in the parenchyma. Numbers of cells in 300 lobar dispersions of lungs from mice in these experiments showed no substantial impact of 301 PARP14 inhibitor on the increases elicited by allergic sensitization followed by inhaled 302 rechallenge (Table 1) . Although a trend toward modest reduction was observed for the numbers 303 of B cells and neutrophils (PMN) with a modest reduction in CD4 + T cells in females, flow 304 cytometric characterizations did not reveal statistically significant changes in major cell types or 305 subsets (Table 1 ). These changes suggest that inhibition of PARP14 at the recall stage of allergic 306 lung inflammation in vivo may have a modest effect on recruitment of several types of immune 307 cell, but we conclude that the magnitude of decrease in mucus over-production was largely 308 uncoupled from global indices of inflammatory cell recruitment. 309 310 Reduced IL-4 production after TCR stimulation of pulmonary infiltrate. 311

One potential explanation for capacity of a PARP14-selective inhibitor to reduce induced mucus accumulation would be that although the extent of infiltration was similar, the 313 amount of type 2 cytokine release would be diminished. To test this possibility, equal numbers of 314 cells in the lung suspensions were stimulated via the TCR to gauge T cell-specific effects. 315

Activation by a combination of phorbol ester (PMA) and calcium ionophore was also performed 316 since these stimuli can also elicit cytokines from mast cells, basophils, and ILC as potential 317 sources of IL-4 or -13. The results show that IL-4 production was dramatically increased by 318 allergic sensitization, and this effect was blunted by the treatment with PARP14 inhibitor (Fig.  319   4A) . Surprisingly, however, this reduction was only observed with male subjects (Fig. 4B , C) 320

and was not a function of the frequency of Th2 cells as judged by flow cytometry after staining 321 of intracellular IL-4. Consistent with the IL-4 data, secreted type 2 cytokines IL-5 and IL-13 also 322 were reduced after re-stimulation of lung cells from male but not female mice (Fig. 4D, E) . 323

There is evidence that PARP14, by an unknown mechanism, can promote Th17 differentiation of 324 naïve T cells (36). IL-17 production by the same cell suspensions was also reduced with lung 325 cells from male subjects treated with PARP14 inhibitor after either T cell-specific or broadly 326 acting stimuli ( Fig. 4F & G, respectively) . Nonetheless, IL-17 production after stimulation of 327 lung cells from RBN2759-treated females was indistinguishable from the controls (not shown). 328

Moreover, production of the T cell-specific cytokine IL-2 and the pro-inflammatory cytokine 329 TNF-α were each lower in the inhibitor-treated males and undetectable in the absence of 330

Alternaria sensitization (Fig. 4F & G) . These were cytokine-specific effects and not a cellular 331 toxicity in that cytokines such as IL-10 were similar in the samples from treated, vehicle control, 332 and non-sensitized mice (Fig. 4F & G) . We conclude that despite the lack of effect on overall 333 numbers of inflammatory cells in the lungs or BAL fluid of inhibitor-treated Alternaria-334 challenged mice, treatment of males with the drug prior to and during re-challenge attenuates 335 type 2 cytokines (IL-4, -5, and -13) as reducing the capacity to produce IL-2, TNF-α, and IL-17. 336 337 Inhibition of allergy-associated increase in IgE. 338

The induction of IgE is one of the first responses to IL-4 to be identified and increased total 339 IgE levels in humans are a hallmark of atopy. In parallel with its promotion of isotype switching 340

to IgH Cε (32) and Cγ1, this cytokine inhibits switching to Cγ2a/c and levels of IgG2a/c (31). 341 Accordingly, we analyzed the relative concentrations of antibodies of these isotypes in 342

Alternaria-challenged mice and non-immunized controls. IgE levels in sera of both male and 343 female mice increased dramatically with allergic sensitization (Fig. 5A -C) . This effect was 344 substantially reduced in female as well as male mice pre-treated with RBN2759 when compared 345 to vehicle controls ( Fig. 5A-C) . A reciprocal effect was observed for IgG2a, whose circulating 346 levels were reduced by allergic sensitization in vehicle-treated mice, whereas the mice subjected 347 to PARP14 inhibition exhibited levels of IgG2a indistinguishable from non-sensitized controls 348 ( Fig. 5D ). Unlike IgE, the IgG1 isotype is robustly induced even with short-term primary 349 exposure to antigen, and circulating IgG has a far longer half-life than IgE due to selective FcRn-350 mediated re-uptake of IgG via FcRn. Moreover, although promoted by IL-4, IgG1 induction can 351 be IL-4-independent. Of note, IgG1 levels in sera of inhibitor-treated mice and vehicle controls 352 did not differ (Fig. 5E ). Moreover, an ELISA that allowed reliable detection of specific IgG1 detected no effect of RBN2759 on specific antigen (Fig. 5F ). We conclude that 354 specific inhibition of the ADP-ribosyl monotransferase activity in PARP14 impacted the nature 355 of an antibody response in vivo. Thus, RBN2759 interfered with the capacity to generate the 356 STAT6-and IL-4-dependent IgE isotype upon sensitization and challenge of both males and 357 females, whereas long-lived IgG1 was unaffected. 358

In addition to reduced IgE responses to ovalbumin in PARP14-deficient mice, in vitro 360 evidence supported both B cell-intrinsic and cell-extrinsic mechanisms (36). To test if the finding 361 of reduced IgE depended on ADP-ribosylation by PARP14, we activated B cells with either LPS 362 or by cross-linking CD40, cultured them in IL-4 with addition either of vehicle of inhibitor, and 363 measured the secreted IgE. RBN2759 reduced IgE production to an extent almost as substantial 364 as the overall effect in males in vivo (Fig. 6A, B) , including at 0.33 µM (Fig. 6E) , the 365 concentration that was the median trough level in vivo (Fig. 1B) . Relative IgG1 concentrations in 366 the same supernatants were not reduced by inhibitor in the cultures (Fig. 6C, D) . Although IL-4 367 can promote B cell proliferation and survival in a PARP14-dependent manner (66), this effect 368

was not likely to be the basis for reduced IgE caused by RBN2759 as the compound did not 369 substantially reduce the cell numbers of these cultures (Table 2) . 370 371 372

While a large percentage of human populations has been shown to be reactive to A. 374 alternata, patients previously diagnosed with asthma are at higher risk of hospital admission or 375 death upon exposure to Alternaria (56, 57) . Using an extract of this clinically relevant 376 aeroallergen in a mouse model of allergic lung inflammation, our results show that an inhibitor 377 of catalytic function highly selective for the ADP-ribosyltransferase of PARP14 (alternatively 378 designated ARTD8) is biologically active. Of note, even after having first sensitized subjects by 379 repeated antigen inhalations, treatment with RBN2759 mitigated both the allergen-induced 380 increases of bronchial mucus and IgE. These findings suggest that the approach of inhibiting the 381 catalytic function of PARP14 has therapeutic potential in patients, in that the drug was effective 382 in a recall model in mice that were already sensitized to the aeroallergen. 383 384 Prior work had indicated that ovalbumin-induced allergic lung responses were reduced when 385 mice lack PARP14 (36, 37). However, PARP14 has several functional domains other than the 386 conserved catalytic domain towards its C terminus (38, 40, 41, 45, 46 reduced a subset of cytokine readouts but did not affect some other cytokine levels (37). The 398 published interpretation of this result is at best complex and fraught, as the IC50 of PJ34 for 399 PARP14 (1-10 µM) is ~100-fold less favorable than for PARP1 and PARP2 (48) . Moreover, 400 inactivation of PARP1 either by genetic or a more specific pharmacological agent blunted 401 ovalbumin-induced allergic lung inflammation and type 2 cytokines (49-53). Of note, assays of 402 RBN2759 indicated that there is a >1000-fold higher IC50 for any affect on PARP1 or any other 403 polyPARP, and >300-fold selectivity relative to the other enzymes that catalyze ADPr 404 modifications (55). Although the data show that peak blood concentrations of the agent in this 405 study (~1.3 -4 µM) might transiently exceed the IC50 of some other PARPs, the trough 406 concentrations were well below the IC50 of all the ADP-ribosyltransferases other than PARP14. 407

Together with the lack of any heterozygote phenotype (Cho SH, Boothby, M, unpublished 408 observations), it is very unlikely that the in vivo target of RBN2759 is either PARP1 or any of 409 the other (ADP-ribosyl)polymerases. 410

The issue of which ART and PARP enzymes are subject to inhibition of catalysis bears on 412 the risk-benefit balance therapeutic potential of a given agent in the context of specific disease 413 targets. PARP1/2 inhibitors are approved for indications in human cancer but not without dose-414 limiting toxicities (69-71), for which the duration of treatment will be shorter and the natural 415 history of untreated disease more dire than in allergic diseases or asthma. Thus, what likely are 416 on-target toxicities or side effects do not undermine a favorable risk-benefit relationship in 417 cancer yet would be unsuitable for asthma. The need for sufficient specificity even among mono-418

ARTs (also termed mono-PARPs) is underscored by work in which a PARP7-specific inhibitor 419 enhances type I interferon responses for potential use in cancer (72, 73). Accordingly, even a less 420 selective mono-ART inhibitor would carry risks of enhancing innate inflammatory cytokines in 421 conditions in which type II (IL-4/5/13-driven) inflammation is the main target. Of note, neither 422 PARP14-deficient nor RBN2759-treated mice have exhibited long-or short-term signals of 423 abnormal health. Moreover, although anti-viral IgA was reduced after infection of Parp14 -/-424 mice with mouse-adapted human metapneumovirus, a major cause of viral respiratory disease, 425 illness was not worse (36). Together, these points suggest that chronic treatment with the 426 selective catalytic inhibitor may prove well tolerated in humans as well as effective in the setting 427 of type II inflammation. The findings here suggest that highly selective catalytic inhibitors of this 428 type will also be helpful in research outside the field of allergic disease research. For instance, 429 several separable steps in the replication of diverse viruses require their encoded activity of 430 macro domains for binding to ADPr, or removal of mono-ADPr from unknown protein targets, 431 or both (74) (75) (76) (77) (78) (79) (80) (81) (82) (83) (84) (85) (86) . Especially since SARS-CoV are among species that use these mechanisms, there 432 will be value in identifying which specific ART enzymes are essential for the endogenous 433 modifications that the virus needs to erase in order to replicate. 434 435

The present body of work both raises intriguing new questions and has inherent limitations. 437

Among these are mechanistic issues, most of all in regards to a sexual disparity (87). In favor of 438 likely efficacy, positive data were obtained for the primary endpoints -mucus scoring and IgE -439 with both male and female mice and the effect magnitudes for these findings were similar in the 440 two sexes. An encouraging point in support of the findings here is that reductions in BAL and 441 lung inflammation as well as type II cytokines have now been observed in fully independent 442 preliminary replication work with different experimentalists, source of BALB/c male mice 443 (Charles River rather than JAX), mouse colony, and batch of Alternaria extract. Nonetheless, 444 later studies would be needed to test whether or not therapeutic efficacy will extend to inbred 445 strains of mice with different patterns of immunity (e.g., C57BL/6; A/J), aeroallergens other than 446

Alternaria, or to IgE-mediated or allergic disease processes of skin (e.g., eczema) or gut (e.g., 447

food allergy). In addition, the primary endpoint effects in female mice were not accompanied by 448 Accordingly, despite unimpressive results with surface staining for MHC-II and CD206, it is 466 possible that PARP14 inhibition changes the products of alternatively activated macrophages 467 that are key intermediaries in allergic lung inflammation (90). Unfortunately, this avenue of 468 research is so unlikely to be fundable via the US NIH that the probability of developing answers 469 to the questions posed above by that route is vanishingly low or nil despite the promise. As in (A) except that RBN012759 was used at 0.33 µM. 863 b. Cells were activated with soluble αCD40 (1 µg/mL) and cultured in BAFF (10 ng/mL), IL-4 878 (10 ng/mL), and IL-5 (10 ng/mL). 879 c. Cells were activated with LPS (1 µg/mL) and cultured in BAFF (10 ng/mL) plus IL-4 (10 880 ng/mL). 

Forced self-600 modification assays as a strategy to screen monoPARP enzymes

Gene 603 knockout or pharmacological inhibition of poly(ADP-ribose) polymerase-1 prevents lung 604 inflammation in a murine model of asthma

Poly(ADP-ribose) polymerase-1 inhibition prevents eosinophil 607 recruitment by modulating Th2 cytokines in a murine model of allergic airway 608 inflammation: a potential specific effect on IL-5

PARP inhibition by olaparib or gene knockout blocks asthma-like 612 manifestation in mice by modulating CD4(+) T cell function

PARP is activated in human asthma and its inhibition by 616 olaparib blocks house dust mite-induced disease in mice

PARP inhibition by olaparib alleviates chronic 618 asthma-associated remodeling features via modulating inflammasome signaling in mice

In vitro and cellular probes to study PARP enzyme target engagement

Kuntz 626 KW. 2020. A potent and selective PARP14 inhibitor decreases pro-tumor macrophage 627 function and elicits inflammatory responses in tumor explants

Is sensitization 630 to Alternaria alternata a risk factor for severe asthma? A population-based study

Alternaria-induced asthma

IL-17A inhibits airway reactivity induced by 636 respiratory syncytial virus infection during allergic airway inflammation

Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 640 and Th2 cell subsets via distinct signaling pathways

National Heart Lung and Blood Institute 645 (NHLBI) Severe Asthma Research Program (SARP)

Autopsy and imaging studies of mucus in 648 asthma. Lessons learned about disease mechanisms and the role of mucus in airflow 649 obstruction

A critical role for eosinophils in allergic 652 airways remodeling

Airway fibrosis and angiogenesis due to eosinophil trafficking 654 in chronic asthma

Modeling T H 2 responses and airway 657 inflammation to understand fundamental mechanisms regulating the pathogenesis of 658 asthma

IL-17A promotes the exacerbation of IL-33-induced 660 airway hyperresponsiveness by enhancing neutrophilic inflammation via CXCR2 signaling 661 in mice

PARP-14, a member of the B aggressive lymphoma family, transduces 664 survival signals in primary B cells

Ladurner 666 AG. 2005. The macro domain is an ADP-ribose binding module

Macrodomain-containing proteins: 668 regulating new intracellular functions of mono(ADP-ribosyl)ation

PARP inhibitors in cancer diagnosis and therapy

Poly(ADP-ribose) polymerase inhibition: past, present and future

Real world experience of 676 poly (ADP-ribose) polymerase inhibitor use in a community oncology practice

Constitutive aryl hydrocarbon receptor signaling constrains type I interferon-mediated 681 antiviral innate defense

Announces-Dosing-of-First-Patient-in-Phase-1-Clinical-Trial-of-RBN-2397-a-First-In-684 Class-PARP7-Inhibitor-Ribon-Therapeutics-Announces-Dosing-of-First-P

Hergenrother 686 PJ, Leys D, Ahel I. 2012. Structure and mechanism of a canonical poly(ADP-ribose) 687 glycohydrolase

Structural and functional basis for 690 ADP-ribose and poly(ADP-ribose) binding by viral macro domains

Mouse hepatitis virus liver 693 pathology is dependent on ADP-ribose-1''-phosphatase, a viral function conserved in the 694 alpha-like supergroup

Differential activities of cellular and viral macro domain 696 proteins in binding of ADP-ribose metabolites

A family of macrodomain proteins reverses cellular mono-ADP-ribosylation

Macrodomain-containing proteins 702 are new mono-ADP-ribosylhydrolases

Rapid evolution of PARP genes 704 suggests a broad role for ADP-ribosylation in host-virus conflicts

Macro domain from Middle Eastern 709 Respiratory Syndrome Coronavirus (MERS-CoV) is an efficient ADP-ribose binding 710 module: Crystal structure and biochemical studies

Viral Macro 712 domains reverse protein ADP-Ribosylation

ADP-ribosylhydrolase activity of 715

Chikungunya virus macrodomain is critical for virus replication and virulence

ADP-ribosyl-binding and hydrolase activities of the alphavirus nsP3 719 macrodomain are critical for initiation of virus replication

The coronavirus macrodomain is required to prevent PARP-723 mediated inhibition of virus replication and enhancement of IFN expression

Testosterone attenuates group 2 innate lymphoid cell-mediated airway 728 inflammation

PARP9 and PARP14 cross-regulate macrophage 732 activation via STAT1 ADP-ribosylation

ARTD10 substrate identification on protein microarrays: regulation of 735 GSK3β by mono-ADP-ribosylation

Contribution of alternatively activated macrophages to 737 allergic lung inflammation: a tale of mice and men

We gratefully acknowledge support of the American Asthma Foundation

Sandler Program in Asthma Research) for the Extension Grant that made possible these studies 742 of the therapeutic potential, as well as that of the Pathology

Department of VUMC to allow a wrap-up after the end of AAF funds. We also are grateful to 744

Wu and the department for flow cytometry capabilities, the cores of VUMC and 745

Vanderbilt University that were used in this work (Flow Cytometry

Molecular Biology reagents), to S. Toki for helpful technical discussions pertaining to the use of 747

Cluster 753 of Differentiation (molecule #3

ELISA, enzyme-linked immunosorbent assay

756 antigen; MAR, mono ADPr; PAR, poly ADPr; PAS, Periodic Acid Schiff; BAL: broncho-757 alveolar lavage

initiated drafting of this manuscript and, with guidance from

handled analyses of drug concentrations and guidance in 764 dosing and delivery

BAL differential counts; L. S. and K. S. generated 765 compound and provided guidance in its use

assisted in design and interpretation 766 of the study as well as providing information on biological data with RBN012759 and editorial 767 input on the manuscript

coordinated liason among Ribon employees and the experimental 768 team at VUMC, along with input on the manuscript

shared initial 769 follow-up findings with independent confirmation of the conclusions herein

provided assistance and guidance on the design and interpretation of the study

772 provided overall guidance and framework, liason with Ribon, wrote the manuscript, and made all 773 final decisions on text and interpretation

are full-time employees of and hold 776 equity interests in Ribon Therapeutics but were recused from analyses and interpretation of the 777 data

holds equity in Regeneron, Inc., which markets 779 a biologic agent used in treatment of allergic diseases and asthma